Literature DB >> 3029283

Glycoproteins of human parainfluenza virus type 3: affinity purification, antigenic characterization and reconstitution into lipid vesicles.

R Ray, R W Compans.   

Abstract

Monoclonal antibodies to the envelope glycoproteins, HN and F, of human parainfluenza virus type 3 were coupled to a Sepharose 4B matrix and used for affinity purification of the viral glycoproteins. The purity of the glycoproteins was demonstrated by SDS-PAGE followed by fluorography or silver staining. The antigenicity of the glycoproteins was determined by immunization of rabbits; polyclonal rabbit antisera demonstrated inhibition of functional activities of the virus glycoproteins. The F glycoprotein, when reconstituted into lipid vesicles, showed distinct spike-like projections similar to those of intact virions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029283     DOI: 10.1099/0022-1317-68-2-409

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

1.  Role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response.

Authors:  R Ray; B J Glaze; R W Compans
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain.

Authors:  R Ray; K Meyer; F K Newman; R B Belshe
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

3.  Association of the parainfluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces.

Authors:  Q Yao; X Hu; R W Compans
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

Review 4.  Current approaches to the development of vaccines effective against parainfluenza viruses.

Authors:  B R Murphy
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

5.  Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene.

Authors:  R Ray; M S Galinski; B R Heminway; K Meyer; F K Newman; R B Belshe
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.